Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Mar;54(3):1248-55.
doi: 10.1128/AAC.01209-09. Epub 2009 Dec 28.

Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals

Affiliations
Randomized Controlled Trial

Lack of pharmacokinetic interaction between amdoxovir and reduced- and standard-dose zidovudine in HIV-1-infected individuals

Selwyn J Hurwitz et al. Antimicrob Agents Chemother. 2010 Mar.

Abstract

Amdoxovir (AMDX) inhibits HIV-1 containing the M184V/I mutation and is rapidly absorbed and deaminated to its active metabolite, beta-D-dioxolane guanosine (DXG). DXG is synergistic with zidovudine (ZDV) in HIV-1-infected primary human lymphocytes. A recent in silico pharmacokinetic (PK)/enzyme kinetic study suggested that ZDV at 200 mg twice a day (b.i.d.) may reduce toxicity without compromising efficacy relative to the standard 300-mg b.i.d. dose. Therefore, an intense PK clinical study was conducted using AMDX/placebo, with or without ZDV, in 24 subjects randomized to receive oral AMDX at 500 mg b.i.d., AMDX at 500 mg plus ZDV at 200 or 300 mg b.i.d., or ZDV at 200 or 300 mg b.i.d. for 10 days. Full plasma PK profiles were collected on days 1 and 10, and complete urine sampling was performed on day 9. Plasma and urine concentrations of AMDX, DXG, ZDV, and ZDV-5'-O-glucuronide (GZDV) were measured using a validated liquid chromatography-tandem mass spectrometry method. Data were analyzed using noncompartmental methods, and multiple comparisons were performed on the log-transformed parameters, at steady state. Coadministration of AMDX with ZDV did not significantly change either of the plasma PK parameters or percent recovery in the urine of AMDX, DXG, or ZDV/GZDV. Larger studies with AMDX/ZDV, with a longer duration, are warranted.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Plasma concentrations (ng/ml; mean ± SD) of AMDX (open symbols) and DXG (closed symbols) by cohort following the administration of 500 mg of AMDX b.i.d. following the initial dose on day 1 (A) and following the day 10 dose (B). Subjects received AMDX alone (○) or with ZDV at 200 mg (▵) or 300 mg (□) b.i.d.
FIG. 2.
FIG. 2.
Plasma concentrations (ng/ml; mean ± SD) of ZDV on day 1 (A) and at steady state (B) by cohort. •, ZDV at 200 mg (n = 2); ▪, ZDV at 300 mg (n = 2); ▴, ZDV at 200 mg plus AMDX at 500 mg b.i.d. (n = 6); ▾, ZDV at 300 mg plus AMDX at 500 mg b.i.d. (n = 6).

Similar articles

Cited by

References

    1. Acosta, E. P., L. M. Page, and C. V. Fletcher. 1996. Clinical pharmacokinetics of zidovudine. An update. Clin. Pharmacokinet. 30:251-262. - PubMed
    1. Barry, M. G., S. H. Khoo, G. J. Veal, P. G. Hoggard, S. E. Gibbons, E. G. Wilkins, O. Williams, A. M. Breckenridge, and D. J. Back. 1996. The effect of zidovudine dose on the formation of intracellular phosphorylated metabolites. AIDS 10:1361-1367. - PubMed
    1. Carpenter, C. C., D. A. Cooper, M. A. Fischl, J. M. Gatell, B. G. Gazzard, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, M. Schechter, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 2000. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society—USA Panel. JAMA 283:381-390. - PubMed
    1. Chen, H., R. F. Schinazi, P. Rajagopalan, Z. Gao, C. K. Chu, H. M. McClure, and F. D. Boudinot. 1999. Pharmacokinetics of (−)-beta-d-dioxolane guanine and prodrug (−)-beta-d-2,6-diaminopurine dioxolane in rats and monkeys. AIDS Res. Hum. Retroviruses 15:1625-1630. - PubMed
    1. Chin, R., T. Shaw, J. Torresi, V. Sozzi, C. Trautwein, T. Bock, M. Manns, H. Isom, P. Furman, and S. Locarnini. 2001. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (−)-beta-d-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-l-arabinofuranosyluracil. Antimicrob. Agents Chemother. 45:2495-2501. - PMC - PubMed

Publication types

MeSH terms